Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:8963405rdf:typepubmed:Citationlld:pubmed
pubmed-article:8963405lifeskim:mentionsumls-concept:C0220847lld:lifeskim
pubmed-article:8963405lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:8963405lifeskim:mentionsumls-concept:C0039195lld:lifeskim
pubmed-article:8963405lifeskim:mentionsumls-concept:C0019721lld:lifeskim
pubmed-article:8963405lifeskim:mentionsumls-concept:C0028612lld:lifeskim
pubmed-article:8963405lifeskim:mentionsumls-concept:C0030956lld:lifeskim
pubmed-article:8963405lifeskim:mentionsumls-concept:C0524910lld:lifeskim
pubmed-article:8963405lifeskim:mentionsumls-concept:C1704632lld:lifeskim
pubmed-article:8963405lifeskim:mentionsumls-concept:C0871261lld:lifeskim
pubmed-article:8963405lifeskim:mentionsumls-concept:C2911692lld:lifeskim
pubmed-article:8963405lifeskim:mentionsumls-concept:C1706817lld:lifeskim
pubmed-article:8963405lifeskim:mentionsumls-concept:C1709915lld:lifeskim
pubmed-article:8963405pubmed:issue6lld:pubmed
pubmed-article:8963405pubmed:dateCreated1996-12-16lld:pubmed
pubmed-article:8963405pubmed:abstractTextHuman leukocyte antigen B44-restricted cytotoxic T lymphocytes (CTLs) recognize an epitope in hepatitis C virus (HCV) nucleoprotein residues 81-100. CTLs that recognize two wild-type peptides 81-100 of HCV genotypes 1b/II and 2a/III were generated from peripheral blood lymphocytes of each of three patients studied. Although CTLs that recognize a wild-type peptide 81-100 of HCV genotypes 1a/I and 2b/IV were not generated from any patient, CTLs that recognize peptide 81-100 of a rare HCV isolate of type 1a/I were generated from two patients. The results suggest that HLA B44-restricted CTLs recognize most, if not all, HCV isolates of types 1b/II and 2a/III and rare variants of type 1a/I and that the wild-type HCV isolates of genotypes 1a/I and 2b/IV may be less immunogenic for HLA B44-restricted CTLs.lld:pubmed
pubmed-article:8963405pubmed:languageenglld:pubmed
pubmed-article:8963405pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8963405pubmed:citationSubsetIMlld:pubmed
pubmed-article:8963405pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8963405pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8963405pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8963405pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8963405pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8963405pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8963405pubmed:statusMEDLINElld:pubmed
pubmed-article:8963405pubmed:monthDeclld:pubmed
pubmed-article:8963405pubmed:issn0944-1174lld:pubmed
pubmed-article:8963405pubmed:authorpubmed-author:OkamotoHHlld:pubmed
pubmed-article:8963405pubmed:authorpubmed-author:KitaHHlld:pubmed
pubmed-article:8963405pubmed:authorpubmed-author:KanekoTTlld:pubmed
pubmed-article:8963405pubmed:authorpubmed-author:OhnishiSSlld:pubmed
pubmed-article:8963405pubmed:authorpubmed-author:ImawariMMlld:pubmed
pubmed-article:8963405pubmed:authorpubmed-author:MoriyamaTTlld:pubmed
pubmed-article:8963405pubmed:authorpubmed-author:HiroishiKKlld:pubmed
pubmed-article:8963405pubmed:issnTypePrintlld:pubmed
pubmed-article:8963405pubmed:volume30lld:pubmed
pubmed-article:8963405pubmed:ownerNLMlld:pubmed
pubmed-article:8963405pubmed:authorsCompleteYlld:pubmed
pubmed-article:8963405pubmed:pagination809-12lld:pubmed
pubmed-article:8963405pubmed:dateRevised2011-11-17lld:pubmed
pubmed-article:8963405pubmed:meshHeadingpubmed-meshheading:8963405-...lld:pubmed
pubmed-article:8963405pubmed:meshHeadingpubmed-meshheading:8963405-...lld:pubmed
pubmed-article:8963405pubmed:meshHeadingpubmed-meshheading:8963405-...lld:pubmed
pubmed-article:8963405pubmed:meshHeadingpubmed-meshheading:8963405-...lld:pubmed
pubmed-article:8963405pubmed:meshHeadingpubmed-meshheading:8963405-...lld:pubmed
pubmed-article:8963405pubmed:meshHeadingpubmed-meshheading:8963405-...lld:pubmed
pubmed-article:8963405pubmed:meshHeadingpubmed-meshheading:8963405-...lld:pubmed
pubmed-article:8963405pubmed:meshHeadingpubmed-meshheading:8963405-...lld:pubmed
pubmed-article:8963405pubmed:meshHeadingpubmed-meshheading:8963405-...lld:pubmed
pubmed-article:8963405pubmed:meshHeadingpubmed-meshheading:8963405-...lld:pubmed
pubmed-article:8963405pubmed:meshHeadingpubmed-meshheading:8963405-...lld:pubmed
pubmed-article:8963405pubmed:meshHeadingpubmed-meshheading:8963405-...lld:pubmed
pubmed-article:8963405pubmed:meshHeadingpubmed-meshheading:8963405-...lld:pubmed
pubmed-article:8963405pubmed:meshHeadingpubmed-meshheading:8963405-...lld:pubmed
pubmed-article:8963405pubmed:meshHeadingpubmed-meshheading:8963405-...lld:pubmed
pubmed-article:8963405pubmed:meshHeadingpubmed-meshheading:8963405-...lld:pubmed
pubmed-article:8963405pubmed:meshHeadingpubmed-meshheading:8963405-...lld:pubmed
pubmed-article:8963405pubmed:year1995lld:pubmed
pubmed-article:8963405pubmed:articleTitleHLA B44-restricted cytotoxic T lymphocyte responses to the peptides of HCV nucleoprotein residues 81-100 in patients with chronic hepatitis C.lld:pubmed
pubmed-article:8963405pubmed:affiliationThird Department of Internal Medicine, University of Tokyo, Japan.lld:pubmed
pubmed-article:8963405pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:8963405pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8963405lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8963405lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8963405lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8963405lld:pubmed